Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 308 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lipitor Clear all

Conditions: Primary Arteriovenous Fistula Failure
Interventions: Atorvastatin 40mg, Placebo; Drug · Other
Lead sponsor: Albany Medical College; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Albany, New York

Conditions: Healthy Volunteers
Interventions: Atorvastatin, ALG-055009, Rosuvastatin; Drug
Lead sponsor: Aligos Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Avascular Necrosis
Interventions: Atorvastatin, MRI, Venipuncture, Placebo; Drug · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Decompensated Liver Cirrhosis, Cirrhosis, Decompensated Cirrhosis of Liver, Decompensated Cirrhosis and Ascites
Interventions: Atorvastatin 20 mg, Placebo; Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Type 2 Diabetes
Interventions: DIO-902; Drug
Lead sponsor: DiObex; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 12
States / cities: Muscle Shoals, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 9 more

Conditions: Hypercholesterolemia
Interventions: Pitavastin 4mg, Atorvastatin 20mg, Rosuvastatin 5mg; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Atorvastatin, Capecitabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Gilbert, Arizona • Greeley, Colorado • Atlanta, Georgia + 2 more

Conditions: Cardiovascular Disease, Cerebrovascular Disorders
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years and older
Enrollment: 26,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Healthy
Interventions: atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypercholesterolemia
Interventions: Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 76
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more

Conditions: Hypercholesterolemia
Interventions: AVE5530, atorvastatin, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: COVID-19
Interventions: Atorvastatin; Drug
Lead sponsor: Mount Auburn Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Hyperlipidemia, Dyslipidemia
Interventions: torcetrapib/atorvastatin, ezetimibe/simvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 123
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more

Conditions: Male Erectile Disorder, Prostate Adenocarcinoma, Erectile Dysfunction, CTCAE, Impotence
Interventions: Atorvastatin, Pentoxifylline, Vitamin E Compound; Drug · Dietary Supplement
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoporosis
Interventions: Atorvastatin; Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 6 Years to 25 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Traumatic Brain Injury, Post-traumatic Stress Disorder
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Hypercholesterolemia
Interventions: ETC-1002, Placebo, Statin Therapy; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 40
States / cities: Muscle Shoals, Alabama • Chandler, Arizona • Chino, California + 36 more

Conditions: Polycystic Ovary Syndrome
Interventions: Lipitor, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Gynecologic Oncological Pelvic/Abdominal Surgery
Interventions: atorvastatin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hypertension
Interventions: atorvastatin, placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 20 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Carotid Artery Stenosis, Strokes
Interventions: Statin, Atorvastatin, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Ridgewood, New Jersey • Albany, New York • Buffalo, New York + 1 more

Conditions: Hypercholesterolemia
Interventions: CAT-2054, Placebo, CAT-2054-C, Atorvastatin; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Acute Myocardial Infarction
Interventions: Atorvastatin calcium, Inactive Placebo; Drug
Lead sponsor: The Western Pennsylvania Hospital; Other
Eligibility: 25 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Kidney Cancer, Renal Cell Carcinoma
Interventions: Zoledronate, Atorvastatin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

High-intensity Atorvastatin for Arteriovenous Fistula Failure (HAFF): A Feasibility Pilot Study

A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)

Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus

Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis

Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients

A Study Comparing CoQ10 Levels While Taking 3 Different Statins

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies

Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

Atorvastatin as Adjunctive Therapy in COVID-19

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer

Atorvastatin (Lipitor) to Prevent Bone Pain

Mission Connect Mild Traumatic Brain Injury (TBI) Integrated Clinical Protocol

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol

High-dose Periop Statins for Prevention of DVT

The Effect of Statin Use on Vascular Function in Hypertensive Subjects

Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

To Investigate the Role of Upstream High Dose Statin in STEMI

Zoledronate With Atorvastatin in Renal Cell Carcinoma